Drug Utilization Review (DUR) Meeting Minutes
September 12, 2011

Members Present: Norman Byers, John Savageau, David Clinkenbeard, Russ Sobotta, Cheryl Huber, Greg Pfister, Patricia Churchill, Steve Irsfeld, James Carlson, Todd Twogood, Carlotta McCleary
Members Absent: Carrie Sorenson, Leann Ness, Kim Krohn, Jeffrey Hostetter
Medicaid Pharmacy Department: Brendan Joyce, Gary Betting
HID Staff Present: Candace Rieth

Chair, G. Pfister called the meeting to order at 1:03 pm. Chair, G. Pfister asked for a motion to approve the minutes from the September meeting. N. Byers moved that the minutes be approved and P. Churchill seconded the motion. Chair, G. Pfister called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update
B. Joyce informed the board members that there are approximately 64,500 recipients eligible for Medicaid benefits. Approximately 19,200 receive prescriptions. There are approximately 58,160 pharmacy claims per month with a cost of approximately 2.9 million dollars.

Asacol HD Second Review
A motion and second were made at the June meeting to place Asacol HD on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Ophthalmic Antihistamines Second Review
A motion and second were made at the June meeting to place Ophthalmic Antihistamines on prior authorization. The topic was brought up for a second review. There was no public comment. Brendan will determine if OTC manufacturers of ophthalmic antihistamines provide federal rebates. If they do, OTC products will be covered. After discussion, Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Horizant Second Review
A motion and second were made at the June meeting to place Horizant on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Daliresp Second Review
A motion and second were made at the June meeting to place Daliresp on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Narcotics with high dose acetaminophen Second Review
A motion and second were made at the June meeting to place narcotics with acetaminophen (other than 5/325 and 10/325) on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Yearly PA Review
The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. DAW,

Amrix/Fexmid, Xenical, Zanaflex, Ketek, and Aczone forms and criteria were reviewed. No changes were made.

Cetraxal Review
B. Joyce reviewed Cetraxal information with the Board. There was no public comment. After discussion, the board tabled the topic.

Dificid Review
B. Joyce reviewed Dificid information with the Board. There was no public comment. After discussion, T. Twogood made a motion to place Dificid on prior authorization. G. Pfister seconded the motion. This topic will be brought up at the next meeting for finalization.

New Oral Anticoagulants Review
B. Joyce reviewed new oral anticoagulants information with the Board. J. Robinson, representing Boehringer Ingelheim, spoke regarding Pradaxa. J. Stoffel, representing Janssen Scientific Affairs, spoke regarding Xarelto. After discussion, J. Savageau made a motion to place Pradaxa on prior authorization. G. Pfister seconded the motion. This topic will be brought up at the next meeting for finalization.

Hereditary Angioedema Review
B. Joyce reviewed products used to treat Hereditary Angioedema with the Board. L. Smith, representing Shire, spoke regarding Firazyr. After discussion, C. Huber made a motion to place these agents on prior authorization. P. Churchill seconded the motion. This topic will be brought up at the next meeting for finalization.

Avandia Update
B. Joyce updated the board on the recent FDA safety announcement regarding Avandia. Because Avandia will only be available through a Risk Evaluation and Mitigation Strategy (REMS) system, the board chose to not make any changes to Avandia coverage.

Simvastatin Update
B. Joyce updated the board on the recent FDA safety announcement regarding high dose simvastatin.

Hepatitis C Update
B. Joyce reviewed the current PA form for Hepatitis C including the two new agents on the market, Victrelis and Incivek. Board members recommended that the form have a space for genotype.

Criteria Recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. P. Churchill moved to approve the new criteria and N. Byers seconded the motion. Chair, G. Pfister called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held December 5, 2011. P. Churchill made a motion to adjourn the meeting. N. Byers seconded. The motion passed with no audible dissent. Chair G. Pfister adjourned the meeting at 3:00 pm.